Aim: To assess factors affecting HV during triptorelin suppression treatment for CPP.
Materials and methods: Forty-six girls with CPP, with mean age at diagnosis 8.4 yrs who presented with signs and symptoms of puberty before the age of 8 years and were treated with triptorelin for at least 2 years, were studied. All girls were categorized into three groups according to the difference between bone age (BA) and chronological age (ΔBA-CA): group I with ΔBA-CA<11.99 months, group II with ΔBA-CA between 12 and 23.99 months and group III with ΔBA-CA>24 months. Furthermore, girls were categorized in two groups: girls with BA before treatment initiation ≤10 years and girls with BA >10 years. Four groups were formed according to Tanner breast staging: group A,B,C,D with breasts TII, TII-III, TIII and TIII-IV respectively.
Results: A statistically significant difference in mean HV during the 2nd year of treatment was observed between group I (5.99±2.21), group II (3.87±1.46) and group III (3.09±1.47) (P=0.012, AN.O.VA). Mean HV during the 2nd year of treatment was statistically higher in girls with BA before treatment ≤10 years (5.78±1.75) compared to girls with BA before treatment >10 years (3.17±1.27) (P=0.0001, t-test). A statistically significant difference in mean HV during the 1st year of treatment was observed between group A (6.32±0.96), group B (5.56±0.97), group C (4.96±1.07), and group D (4.26±1.66) (P=0.05, Kruskal-Wallis AN.O.VA). HV during the second year of treatment could be statistically predicted using bone age (P=0.002) and weight (P=0.036) before treatment initiation as independent factors in multivariate linear regression model, according to the following equation: HV2nd year=15,026−0,702X(BA)-0,0892X(W).
Conclusions: Bone age, Tanner breast stage and weight seem to be important factors affecting HV during triptorelin therapy for CPP.